Perrigo
Headquartered in Ireland, Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products and receives royalties from Multiple Sclerosis drug Tysabri.
In 2013 it acquired Irish pharma company Elan.
Financial Data
-
31st Dec 18 Source: CRO
- €4.2 billion turnover
-
€255.3 million
profit - 10,400 employees
-
31st Dec 17 Source: CRO
- €4.1 billion turnover
-
€229.2 million
profit - 10,400 employees
- 4 more years available »
Ranking
By Turnover
(€4.2 billion)- 29th in Top Companies
- 6th in Health
- 5th in Pharma
By Employees
(10,400)- 22nd in Top Companies
- 4th in Health
- 4th in Pharma
-
- 10,400
- €4.2 billion
Employees
- Murray S. Kessler CEO/Managing Director
Latest News
- 8:30am Ryanair cuts growth forecast, confirms it is looking at base closures
- 7:53am INM sets date for High Court to seek approval for Mediahuis deal
- 7:31am CRH to sell European distribution business to Blackstone funds
- 6:30am Fake fibre ads, taxpayers and Ryanair airports, and the best restaurant deals
- 5:45am Telecoms companies to face clampdown on ‘fake fibre’ adverts